These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 37424676)

  • 41. Cost-effectiveness analysis of hepatitis B vaccine booster in children born to HBsAg-positive mothers in rural China.
    Wang Y; Shi JF; Wang L; Yan Y; Yao H; Dai M; Chen T; Qu C
    Int J Infect Dis; 2019 Jan; 78():130-139. PubMed ID: 30466898
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Economic evaluation of universal newborn hepatitis B vaccination in China.
    Lu SQ; McGhee SM; Xie X; Cheng J; Fielding R
    Vaccine; 2013 Apr; 31(14):1864-9. PubMed ID: 23384752
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Tenofovir disoproxil fumarate in pregnancy for prevention of mother to child transmission of hepatitis B in a rural setting on the Thailand-Myanmar border: a cost-effectiveness analysis.
    Bierhoff M; Angkurawaranon C; Rijken MJ; Sriprawa K; Kobphan P; Nosten FN; van Vugt M; McGready R; Devine A
    BMC Pregnancy Childbirth; 2021 Feb; 21(1):157. PubMed ID: 33618698
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cost-effectiveness and cost-utility of traditional and telemedicine combined population-based age-related macular degeneration and diabetic retinopathy screening in rural and urban China.
    Li R; Yang Z; Zhang Y; Bai W; Du Y; Sun R; Tang J; Wang N; Liu H
    Lancet Reg Health West Pac; 2022 Jun; 23():100435. PubMed ID: 35355615
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Real-world cost-effectiveness of pan-genotypic Sofosbuvir-Velpatasvir combination versus genotype dependent directly acting anti-viral drugs for treatment of hepatitis C patients in the universal coverage scheme of Punjab state in India.
    Chugh Y; Dhiman RK; Premkumar M; Prinja S; Singh Grover G; Bahuguna P
    PLoS One; 2019; 14(8):e0221769. PubMed ID: 31465503
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cost-effectiveness of screening and vaccinating Asian and Pacific Islander adults for hepatitis B.
    Hutton DW; Tan D; So SK; Brandeau ML
    Ann Intern Med; 2007 Oct; 147(7):460-9. PubMed ID: 17909207
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Economic Analysis and Budget Impact of Tenofovir and Entecavir in the First-Line Treatment of Hepatitis B Virus in Italy.
    Ruggeri M; Basile M; Coretti S; Drago C; Cicchetti A
    Appl Health Econ Health Policy; 2017 Aug; 15(4):479-490. PubMed ID: 28197805
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Assessing the clinical and economic impact of increasing treatment uptake in chronic hepatitis B infection using a Markov model.
    Chinnaratha MA; Kaambwa B; Woodman RJ; Fraser RJ; Wigg AJ
    J Gastroenterol Hepatol; 2017 Jul; 32(7):1370-1377. PubMed ID: 28002881
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Long-term follow-up of cumulative incidence of hepatocellular carcinoma in hepatitis B virus patients without antiviral therapy.
    Jiang XY; Huang B; Huang DP; Wei CS; Zhong WC; Peng DT; Huang FR; Tong GD
    World J Gastroenterol; 2021 Mar; 27(11):1101-1116. PubMed ID: 33776376
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cost-Effectiveness Analysis of Oral Direct-Acting Antivirals for Chinese Patients with Chronic Hepatitis C.
    Chen P; Jin M; Cao Y; Li H
    Appl Health Econ Health Policy; 2021 May; 19(3):371-387. PubMed ID: 33210262
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The cost-effectiveness of treating chronic hepatitis B patients in a median endemic and middle income country.
    Toy M; Onder FO; Idilman R; Kabacam G; Richardus JH; Bozdayi M; Akdogan M; Kuloglu Z; Kansu A; Schalm S; Yurdaydin C
    Eur J Health Econ; 2012 Oct; 13(5):663-76. PubMed ID: 22815098
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Universal Hepatitis B Antibody Screening and Vaccination in Pregnancy: A Cost-Effectiveness Analysis.
    Prabhu M; Susich MK; Packer CH; Hersch AR; Riley LE; Caughey AB
    Obstet Gynecol; 2022 Mar; 139(3):357-367. PubMed ID: 35115449
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Economic evaluation of pan-genotypic generic direct-acting antiviral regimens for treatment of chronic hepatitis C in Iran: a cost-effectiveness study.
    Tasavon Gholamhoseini M; Sharafi H; Hl Borba H; Alavian SM; Sabermahani A; Hajarizadeh B
    BMJ Open; 2022 Jun; 12(6):e058757. PubMed ID: 35676019
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cost-Effectiveness of Access Expansion to Treatment of Hepatitis C Virus Infection Through Primary Care Providers.
    Rattay T; Dumont IP; Heinzow HS; Hutton DW
    Gastroenterology; 2017 Dec; 153(6):1531-1543.e2. PubMed ID: 29074450
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Analysis of the cost-effectiveness of antiviral therapies in chronic hepatitis B patients in Korea].
    Kim BK; Kwon SY; Lee CH; Choe WH; Choi HM; Koo HW
    Korean J Hepatol; 2009 Mar; 15(1):25-41. PubMed ID: 19346783
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Application of Bayesian Approach to Cost-Effectiveness Analysis of Antiviral Treatments in Chronic Hepatitis B.
    Zhang H; Huo M; Chao J; Liu P
    PLoS One; 2016; 11(8):e0161936. PubMed ID: 27574976
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cost-effectiveness analysis of recombinant factor IX Fc fusion protein compared with recombinant factor IX for the treatment of moderate-severe to severe hemophilia B in China.
    Zhou T; Wang S; Zhang Y; Wu R; Li H
    Pediatr Blood Cancer; 2023 Jun; 70(6):e30264. PubMed ID: 36815588
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cost-effectiveness of artificial intelligence-assisted liquid-based cytology testing for cervical cancer screening in China.
    Shen M; Zou Z; Bao H; Fairley CK; Canfell K; Ong JJ; Hocking J; Chow EPF; Zhuang G; Wang L; Zhang L
    Lancet Reg Health West Pac; 2023 May; 34():100726. PubMed ID: 37283979
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Screening and early treatment of migrants for chronic hepatitis B virus infection is cost-effective.
    Veldhuijzen IK; Toy M; Hahné SJ; De Wit GA; Schalm SW; de Man RA; Richardus JH
    Gastroenterology; 2010 Feb; 138(2):522-30. PubMed ID: 19879275
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Cost-effectiveness of anti-tumor associated antigen autoantibody screening for hepatocellular carcinoma in the population with chronic hepatitis B-related cirrhosis].
    Zhang M; Li YG; Wang KY; Wang X; Dai LP; Wang P; Ye H; Shi JX; Yang XA; Zhang SX; Zhang JY
    Zhonghua Yi Xue Za Zhi; 2021 Aug; 101(32):2544-2551. PubMed ID: 34407581
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.